Featured Stock: RTX
When RTX (RTX) posted quarterly results, the stock irrationally fell below $115. Buyers stepped in throughout last week, and the stock closed at $125.22. Although the downtrend on the chart is still bearish, investors should add RTX stock to the buy list.RTX is among the defense and aerospace leaders that thrive as the war in Europe continues. In the first quarter, it earned $1.47 a share (non-GAAP). Revenue increased by 5.2% Y/Y to $20.3 billion. For 2025, the firm is forecasting adjusted sales of up to $84 billion, close to analyst estimates.The European Union is ramping up its military spending. It seeks to prepare for potential conflicts through prevention. For example, Poland is increasing its spending to 5%, while the U.K. is considering it and Germany is already committed to it. Raytheon has an opportunity to sell integrated air and missile defense systems. Its battle-tested products include Patriot GEM-T, NASAMS, and Coyote.OpportunityThe trade war adds costs for RTX. The firm has $850 million in costs to manage. This includes mitigations in regulatory, duties, and operational costs. RTX management is not concerned, since it operated effectively in a previously highly inflationary environment.Your TakeawayRTX is ready to manage supply chain disruptions related to tariffs. Investors are confident that the tariff trade war will not hurt RTX’s profits much.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


